Allopurinol in Diabetes Mellitus and Multivessel Coronary Artery Disease
Status:
Unknown status
Trial end date:
2020-01-31
Target enrollment:
Participant gender:
Summary
Atherosclerosis is a progressive disease of the arterial wall, arising from the combination
of endothelial dysfunction and inflammation. This link is exacerbated in diabetic patients.
Uric acid is known to generate oxidative stress and it's elevated levels has been shown to be
associated with cardiac hypertrophy, inflammation, myocardial fibrosis and diastolic
dysfunction. Allopurinol inhibits xanthine oxidase, an enzyme that regulates uric acid
production. In observational studies it has been shown to reduce ischemia, inflammation and
improve coronary flow. The aim of this study is to see whether treatment with Allopurinol in
patients diagnosed with multivessel disease and undergoing treatment with either percutaneous
coronary intervention (PCI) or coronary artery bypass surgery (CABG) , will reduce markers of
inflammation and improve quality of life and major adverse cardiovascular effects (MACE).